Press Releases Related News

Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service

LOUISVILLE, Ky., March 14, 2017 /PRNewswire/ -- Eurofins Genomics, the pioneer of high-throughput oligonucleotide synthesis, announced the U.S. commercial launch of a unique DNA synthesis service based on the company's revolutionary next-generation synthesis platform. The service, which is designed to [...]

By | March 16th, 2017|DNA Synthesis, Industry Providers, News, Press Releases|

BioBright Tools Bring ‘Superpowers’ to the Biology Lab

March 14, 2017 09:00 AM Eastern Daylight Time  BOSTON--(BUSINESS WIRE)--BioBright, a firm developing technologies to enable more precise, more reproducible research protocols in biology, has improved the accuracy of a delicate laboratory technique by more than 20 times in the [...]

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

DUBLIN, Ireland and CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte

BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG [...]

By | March 14th, 2017|News, Press Releases|

Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets

GERMANTOWN, Md., March 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Horizon Discovery enters into R&D and licensing partnership with Amplycell S.A. for bioproduction cell line optimisation

Cambridge, UK and Liege, BE, 8 March 2017 - Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, including the provision of bioproduction cell lines, today announced it has entered into a research and [...]